SCHEMBL6377261

SCHEMBL6377261

O=[N+]([O-])c1ccc(-c2n[nH]c3cc([N+](=O)[O-])ccc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.64
HPGD P15428 1/20 0.64
MAP2K7 O14733 2/20 0.55
ABCC8 Q09428 1/20 0.51
KCNJ11 Q14654 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
CASP3 P42574 1/20 0.50
HTT P42858 1/20 0.50
MMP13 P45452 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
PDPK1 O15530 1/20 0.50
HSP90AB1 P08238 1/20 0.50
FGFR1 P11362 1/20 0.49
FGFR2 P21802 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1513036 0.91 MAPT (0.78) MAPTHPGDMAP2K7ABCC8KCNJ11
Hydrochloric Acid SCHEMBL6370654 0.86 MAPT (0.53) MAPTHPGDMAP2K7ABCC8KCNJ11
Hydrochloric Acid SCHEMBL6370476 0.86 MAPT (0.53) MAPTHPGDMAP2K7ABCC8KCNJ11
SCHEMBL20380220 0.84 HPGD (0.68) MAPTHPGDABCC8KCNJ11NPC1
Hydrochloric Acid SCHEMBL6370613 0.82 MAPT (0.51) MAPTHPGDMAP2K7NPC1RAB9A
SCHEMBL2860859 0.82 MAP2K7 (0.59) MAPTHPGDMAP2K7RAB9AHTT
SCHEMBL6376401 0.82 MAPT (0.61) MAPTHPGDMAP2K7RAB9AMAP2K4
Hydrochloric Acid SCHEMBL6370628 0.81 HPGD (0.60) MAPTHPGDMAP2K7RAB9AMAP2K4
SCHEMBL30833662 0.80 DAO (0.51) MAPTHPGDMAP2K7NPC1RAB9A
SCHEMBL921416 0.80 DAO (0.51) MAPTHPGDMAP2K7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US claimed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP claimed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO claimed
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAPT 2429/4885HPGD 3111/4885MAP2K7 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.